Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Lenz

Showing results (161-170 of 294) with videos related to

Pageof 30
Sort By:
Leukemia Research|December 24, 2025
Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemiaJulian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, et al.
Haematologica|October 15, 2020
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA studyChristopher R Bolen, Magdalena Klanova, Marek Trneny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2005
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)Georg Lenz, Martin Dreyling, Eva Hoster, et al.
Annals of Hematology|February 6, 2025
Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemiaEvgenii Shumilov, Paolo Mazzeo, Marcel Trautmann, et al.
Bone Marrow Transplantation|February 1, 2020
Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemiaKlaus Wethmar, Svenja Matern, Eva Eßeling, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomasChristoph Schliemann, Teresa Hemmerle, Andrew F Berdel, et al.
The European Respiratory Journal|June 2, 2018
Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancerJan-Henrik Mikesch, Daniela Schwammbach, Wolfgang Hartmann, et al.
Cancers|July 19, 2020
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like TypeValdemar Priebe, Giulio Sartori, Sara Napoli, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2013
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphomaMatthias Pfeifer, Michael Grau, Dido Lenze, et al.
Blood Advances|November 7, 2023
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stressBeatriz Gomez Solsona, Heike Horn, Anja Schmitt, et al.
Pageof 30

Showing results (161-170 of 294) with videos related to

Sort By:
Pageof 30
Leukemia Research|December 24, 2025
Relapse after allogeneic hematopoietic stem cell transplantation in patients with active acute myeloid leukemiaJulian Ronnacker, Marc-Andre Urbahn, Christian Reicherts, et al.
Haematologica|October 15, 2020
Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA studyChristopher R Bolen, Magdalena Klanova, Marek Trneny, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 26, 2005
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)Georg Lenz, Martin Dreyling, Eva Hoster, et al.
Annals of Hematology|February 6, 2025
Functional apoptosis profiling reveals vulnerabilities in T-cell large granular lymphocytic leukemiaEvgenii Shumilov, Paolo Mazzeo, Marcel Trautmann, et al.
Bone Marrow Transplantation|February 1, 2020
Monitoring minimal residual/relapsing disease after allogeneic haematopoietic stem cell transplantation in adult patients with acute lymphoblastic leukaemiaKlaus Wethmar, Svenja Matern, Eva Eßeling, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomasChristoph Schliemann, Teresa Hemmerle, Andrew F Berdel, et al.
The European Respiratory Journal|June 2, 2018
Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancerJan-Henrik Mikesch, Daniela Schwammbach, Wolfgang Hartmann, et al.
Cancers|July 19, 2020
Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like TypeValdemar Priebe, Giulio Sartori, Sara Napoli, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 11, 2013
PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphomaMatthias Pfeifer, Michael Grau, Dido Lenze, et al.
Blood Advances|November 7, 2023
Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stressBeatriz Gomez Solsona, Heike Horn, Anja Schmitt, et al.
Pageof 30